<html>
<head>PUBMED IDs for CD168</head>
<body bgcolor='#C5F0F2'><h1>CD168</h1><a href='https://pubmed.ncbi.nlm.nih.gov/11596057/'>Identification of sequence, protein isoforms, and distribution of the hyaluronan-binding protein RHAMM in adult and developing rat brain.</a> October 12  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/15627212/'>Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.</a> January 1  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/15627212/'>Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.</a> January 1  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/16773189/'>Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.</a> June 15  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/17145602/'>Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.</a> December 6  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/17145599/'>CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.</a> December 6  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/18174258/'>Androgen receptor regulates CD168 expression and signaling in prostate cancer.</a> January 5  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/18174257/'>Decreased risk of colorectal cancer with the high natural killer cell activity NKG2D genotype in Japanese.</a> January 5  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/19724689/'>RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.</a> November 11  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/19857547/'>Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas.</a> January 12  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/20970674/'>Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.</a> March 29  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21896084/'>Gastric cancer: basic aspects.</a> December 20  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/22532518/'>RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.</a> July 9  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23166824/'>Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogels.</a> April 30  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23733927/'>Hydrogels that mimic developmentally relevant matrix and N-cadherin interactions enhance MSC chondrogenesis.</a> September 5  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24092768/'>Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer.</a> December 23  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24966934/'>A case of cervical cancer expressed three mRNA variant of Hyaluronan-mediated motility receptor.</a> February 24  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/26295306/'>Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.</a> July 23  2015<br></body></html>
